GlassScriptPhysician profile
Anju Mendiratta
NPI 1578533105
$1,963.49
in general payments reported to CMS, 2019-2025
26 companies · $676 in 2025
The $676 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.72 · 2020: $33.19 · 2021: $43.88 · 2022: $333 · 2023: $315 · 2024: $498 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Education: $69.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.62 |
| Education | $69.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $331.89 | 2021-2025 | Farxiga, Lokelma, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $215.60 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $170.58 | 2022-2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $139.41 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $128.02 | 2022-2025 | Tarpeyo |
| Corcept Therapeutics | $121.93 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.74 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $106.65 | 2019-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $75.92 | 2024-2025 | Vafseo |
| Horizon Therapeutics Plc | $62.10 | 2020-2023 | Krystexxa |
| Vifor Pharma, INC. | $57.93 | 2019-2025 | Veltassa |
| Amgen INC. | $47.57 | 2022-2025 | Tavneos |
| Scpharmaceuticals INC. | $45.04 | 2024-2025 | |
| Travere Therapeutics, INC. | $44.92 | 2025 | |
| Kyowa Kirin, INC. | $41.12 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $36.15 | 2024 | Gvoke Hypopen |
| Genzyme Corporation | $30.81 | 2023 | |
| Aurinia Pharma U.S., INC. | $29.87 | 2022-2023 | Lupkynis |
| Nxstage Medical, INC. | $28.85 | 2021-2025 | Nxstage System One |
| Opko Pharmaceuticals, LLC | $27.27 | 2023 | Rayaldee |
| Ardelyx, INC. | $22.45 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $20.87 | 2024 | Benlysta |
| Sumitomo Pharma America, INC. | $17.50 | 2023 | Gemtesa |
| Medtronic, INC. | $16.91 | 2022 | |
| Abbvie INC. | $15.51 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.88 | 2023 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anju Mendiratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.